RaeSedo
Private Company
Funding information not available
Overview
RaeSedo is a private, preclinical-stage biotech developing SP-A-derived peptide therapeutics for asthma, targeting underlying inflammation and infection-driven exacerbations. The company's approach is based on the discovery that a subset of asthma patients have low or non-functional SP-A, a natural lung defense protein. Led by a team with expertise in lung immunology, clinical asthma, and business strategy, RaeSedo aims to address a critical unmet need in a large and costly disease market. The technology has shown promise in inducing eosinophil cell death and combating Mycoplasma pneumoniae infections, which are key drivers of severe asthma.
Technology Platform
Platform based on Surfactant Protein-A (SP-A) peptidomimetics. Identified a 10-20 amino acid sequence that replicates SP-A's anti-inflammatory and anti-infective activities, including induction of eosinophil apoptosis and action against Mycoplasma pneumoniae.
Opportunities
Risk Factors
Competitive Landscape
Competes in the severe asthma market dominated by biologics targeting IL-5 (e.g., mepolizumab), IL-4/13 (e.g., dupilumab), and IgE (omalizumab). Differentiation is based on a novel, natural host-defense mechanism targeting both inflammation and infection, unlike current pathway-specific inhibitors.